A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer-Reference-Cited by-同舟云学术

A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer

Published:2015-09 Issue:13 Volume:51 Page:1714-1724
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Hussain Maha,Rathkopf Dana,Liu Glenn,Armstrong Andrew,Kelly Wm. Kevin,Ferrari Anna,Hainsworth John,Joshi Adarsh,Hozak Rebecca R.,Yang Ling,Schwartz Jonathan D.,Higano Celestia S.

Funder

Eli Lilly and Company

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference36 articles.

1. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004

2. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer;Petrylak;N Engl J Med,2004

3. The changing natural history of metastatic prostate cancer;Alva;Cancer J,2013

4. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth;Khandwala;Endocr Rev,2000

5. Insulin-like growth factor I secreted from prostate stromal cells mediates tumor-stromal cell interactions of prostate cancer;Kawada;Cancer Res,2006

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancement in Mechanistic Alteration of IGFs Family of Receptors to Target Prostate and Cervical Cancer: An Updated Review;Current Cancer Therapy Reviews;2024-08-19

2. Insulin-like growth factor family and prostate cancer: new insights and emerging opportunities;Frontiers in Endocrinology;2024-05-30

3. Determining the late effect parameter in the Fleming-Harrington test using asymptotic relative efficiency in cancer immunotherapy clinical trials;Journal of Biopharmaceutical Statistics;2023-08-10

4. Emerging Role of IGF-1 in Prostate Cancer: A Promising Biomarker and Therapeutic Target;Cancers;2023-02-17

5. Enzalutamide and olaparib synergistically suppress castration-resistant prostate cancer progression by promoting apoptosis through inhibiting nonhomologous end joining pathway;Asian Journal of Andrology;2023